SUTRO BIOPHARMA, INC. Financing Cash Flow
SUTRO BIOPHARMA, INC. (STRO) reported Financing Cash Flow of $102.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$418.00K.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $103.08M, a 156074.24% increase year-over-year.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$64.00K.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $102.00K, a 89.97% decline year-over-year.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2025 was $44.00K, a 99.95% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2024 was $94.05M, a 31.62% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2023 was $137.55M, a 184.71% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2022 was $48.31M, a 1383.81% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $102.66M 10-Q · filed 2026-08-12 | $102.59M derived: sum of 3 quarters · filed 2026-08-12 | $102.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $103.08M 10-Q · filed 2026-05-14 | $103.01M derived: sum of 2 quarters · filed 2026-05-14 | $103.11M derived: sum of 3 quarters · filed 2026-05-14 | $103.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $38.00K derived: sum of 2 quarters · filed 2026-03-23 | -$22.00K derived: sum of 3 quarters · filed 2026-08-12 | $44.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $42.00K derived: sum of 2 quarters · filed 2026-08-12 | $108.00K 10-Q · filed 2025-11-06 | $84.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.00K 10-Q · filed 2026-08-12 | -$18.00K derived: sum of 3 quarters · filed 2026-08-12 | $999.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $66.00K 10-Q · filed 2026-05-14 | $42.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.06M derived: sum of 3 quarters · filed 2026-05-14 | $97.55M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $993.00K derived: sum of 2 quarters · filed 2026-03-23 | $97.48M derived: sum of 3 quarters · filed 2026-03-23 | $94.05M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $97.51M derived: sum of 2 quarters · filed 2025-11-06 | $94.08M 10-Q · filed 2025-11-06 | $90.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $96.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $93.06M 10-Q · filed 2025-08-07 | $89.94M derived: sum of 3 quarters · filed 2025-08-07 | $84.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$3.43M 10-Q · filed 2025-05-08 | -$6.55M derived: sum of 2 quarters · filed 2025-05-08 | -$12.29M derived: sum of 3 quarters · filed 2025-05-08 | $125.37M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$8.87M derived: sum of 2 quarters · filed 2025-03-13 | $128.80M derived: sum of 3 quarters · filed 2025-03-13 | $137.55M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $131.92M derived: sum of 2 quarters · filed 2024-11-13 | $140.68M 10-Q · filed 2024-11-13 | $152.90M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $137.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $146.42M 10-Q · filed 2024-08-13 | $158.64M derived: sum of 3 quarters · filed 2025-03-13 | $188.49M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $8.76M 10-Q · filed 2024-05-13 | $20.98M derived: sum of 2 quarters · filed 2025-03-13 | $50.83M derived: sum of 3 quarters · filed 2025-03-13 | $56.31M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $12.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $42.07M derived: sum of 2 quarters · filed 2025-03-13 | $47.55M derived: sum of 3 quarters · filed 2025-03-13 | $48.31M 10-K · filed 2025-03-13 |
| 2022-09-30 | $29.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $35.33M derived: sum of 2 quarters · filed 2023-11-13 | $36.09M 10-Q · filed 2023-11-13 | $36.60M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.25M 10-Q · filed 2023-08-10 | $6.75M derived: sum of 3 quarters · filed 2024-03-25 | $7.71M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $760.00K 10-Q · filed 2023-05-15 | $1.27M derived: sum of 2 quarters · filed 2024-03-25 | $2.23M derived: sum of 3 quarters · filed 2024-03-25 | $2.19M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.47M derived: sum of 2 quarters · filed 2024-03-25 | $1.43M derived: sum of 3 quarters · filed 2024-03-25 | $3.26M 10-K · filed 2024-03-25 |
| 2021-09-30 | $963.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $924.00K derived: sum of 2 quarters · filed 2022-11-08 | $2.75M 10-Q · filed 2022-11-08 | $147.60M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.79M 10-Q · filed 2022-08-08 | $146.64M derived: sum of 3 quarters · filed 2023-03-30 | $163.91M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $1.83M 10-Q · filed 2022-05-09 | $146.68M derived: sum of 2 quarters · filed 2023-03-30 | $163.95M derived: sum of 3 quarters · filed 2023-03-30 | $255.37M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $144.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $162.13M derived: sum of 2 quarters · filed 2023-03-30 | $253.54M derived: sum of 3 quarters · filed 2023-03-30 | $269.25M 10-K · filed 2023-03-30 |
| 2020-09-30 | $17.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $108.69M derived: sum of 2 quarters · filed 2021-11-10 | $124.39M 10-Q · filed 2021-11-10 | $122.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $91.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $107.12M 10-Q · filed 2021-08-09 | $105.34M derived: sum of 3 quarters · filed 2022-02-28 | $104.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $15.70M 10-Q · filed 2021-05-07 | $13.92M derived: sum of 2 quarters · filed 2022-02-28 | $12.79M derived: sum of 3 quarters · filed 2022-02-28 | $11.98M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$2.91M derived: sum of 2 quarters · filed 2022-02-28 | -$3.73M derived: sum of 3 quarters · filed 2022-02-28 | -$4.18M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.95M derived: sum of 2 quarters · filed 2020-11-05 | -$2.40M 10-Q · filed 2020-11-05 | $85.45M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$819.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.28M 10-Q · filed 2020-08-06 | $86.58M derived: sum of 3 quarters · filed 2021-03-18 | $136.75M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | -$458.00K 10-Q · filed 2020-05-11 | $87.40M derived: sum of 2 quarters · filed 2021-03-18 | $137.57M derived: sum of 3 quarters · filed 2021-03-18 | $170.34M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $87.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $138.03M derived: sum of 2 quarters · filed 2021-03-18 | $170.80M derived: sum of 3 quarters · filed 2021-03-18 | $170.78M 10-K · filed 2021-03-18 |
| 2018-09-30 | $50.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $82.94M derived: sum of 2 quarters · filed 2019-11-08 | $82.93M 10-Q · filed 2019-11-08 | $82.75M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $32.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $32.76M 10-Q · filed 2019-08-14 | $32.58M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$14.00K 10-Q · filed 2019-05-15 | -$192.00K derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $14.64M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | $14.82M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $177.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |